603259 药明康德
午间休市 12-08 11:29:59
资讯
新帖
简况
药明康德（603259）披露截至11月30日证券变动月报表，12月2日股价下跌3.12%
证券之星 · 12-02
药明康德（603259）披露截至11月30日证券变动月报表，12月2日股价下跌3.12%
摩根大通增持药明康德(02359)约73.65万股 每股作价约102.49港元
智通财经 · 11-26
摩根大通增持药明康德(02359)约73.65万股 每股作价约102.49港元
药明康德：近日股东减持公司总股本的0.40%
每日经济新闻 · 11-26
药明康德：近日股东减持公司总股本的0.40%
药明康德“美颜”三季报：营收增18.6％ 非经常性收益支撑利润 多项指标显露增长隐忧
华夏时报网 · 11-25
药明康德“美颜”三季报：营收增18.6％ 非经常性收益支撑利润 多项指标显露增长隐忧
每周股票复盘：药明康德（603259）可转债悉数转换新增H股1806万股
证券之星 · 11-09
每周股票复盘：药明康德（603259）可转债悉数转换新增H股1806万股
11月7日药明康德现474.2万元大宗交易
证券之星 · 11-07
11月7日药明康德现474.2万元大宗交易
药明康德（603259）披露召开2025年第三季度业绩说明会公告，11月04日股价下跌2.7%
证券之星 · 11-04
药明康德（603259）披露召开2025年第三季度业绩说明会公告，11月04日股价下跌2.7%
药明康德跌3.01% 西部证券上周三维持买入评级
中金财经 · 11-03
药明康德跌3.01% 西部证券上周三维持买入评级
建银国际：上调药明康德(02359)目标价至131港元 维持“跑赢大市”评级
智通财经 · 11-03
建银国际：上调药明康德(02359)目标价至131港元 维持“跑赢大市”评级
中银国际：升药明康德(02359)目标价至127港元 第三季业绩胜预期
智通财经 · 10-30
中银国际：升药明康德(02359)目标价至127港元 第三季业绩胜预期
10月29日增减持汇总：杭氧股份拟增持 药明康德等11股拟减持（表）
新浪证券 · 10-29
10月29日增减持汇总：杭氧股份拟增持 药明康德等11股拟减持（表）
药明康德股东计划减持最多合计2%的A股（股东澄清将削减A股）
美股速递 · 10-29
药明康德股东计划减持最多合计2%的A股（股东澄清将削减A股）
药明康德最新公告：实际控制人控制的股东拟减持不超过2%公司股份
证券之星 · 10-29
药明康德最新公告：实际控制人控制的股东拟减持不超过2%公司股份
业绩、效率与战略的三重奏：药明康德（02359）CRDMO模式2025 Q3全面开花
智通财经 · 10-29
业绩、效率与战略的三重奏：药明康德（02359）CRDMO模式2025 Q3全面开花
高盛：药明康德(02359)上季盈利胜预期 关注新订单动能与临床CRO业务 目标价109.6港元
智通财经 · 10-28
高盛：药明康德(02359)上季盈利胜预期 关注新订单动能与临床CRO业务 目标价109.6港元
【券商聚焦】招银国际维持药明康德(02359)“买入”评级 惟指全面复苏仍需时间
金吾财讯 · 10-28
【券商聚焦】招银国际维持药明康德(02359)“买入”评级 惟指全面复苏仍需时间
高瓴拟斥资28亿买下药明康德旗下康德弘翼和津石医药
雷递网 · 10-28
高瓴拟斥资28亿买下药明康德旗下康德弘翼和津石医药
华宝基金胡洁旗下华宝中证医疗ETF三季报最新持仓，重仓药明康德
证券之星 · 10-28
华宝基金胡洁旗下华宝中证医疗ETF三季报最新持仓，重仓药明康德
大摩：药明康德(02359)有望超越全年收入增长指引 予“增持”评级
智通财经 · 10-27
大摩：药明康德(02359)有望超越全年收入增长指引 予“增持”评级
瑞银：药明康德季绩超预期 上调目标价至138.4港元
新浪港股 · 10-27
瑞银：药明康德季绩超预期 上调目标价至138.4港元
加载更多
公司概况
公司名称：
无锡药明康德新药开发股份有限公司
所属行业：
研究和试验发展
上市日期：
2018-05-08
主营业务：
无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务。公司的服务能力和规模在行业处于领先地位,拥有了多项行业领先的技术和能力。
发行价格：
21.60
{"stockData":{"symbol":"603259","market":"SH","secType":"STK","nameCN":"药明康德","latestPrice":91.3,"timestamp":1765164599000,"preClose":90.4,"halted":0,"volume":21636517,"delay":0,"changeRate":0.01,"floatShares":2473000000,"shares":2984000000,"eps":5.0249,"marketStatus":"午间休市","change":0.9,"latestTime":"12-08 11:29:59","open":90.83,"high":91.8,"low":90.41,"amount":1973000000,"amplitude":0.0154,"askPrice":91.3,"askSize":2,"bidPrice":91.29,"bidSize":12,"shortable":0,"etf":0,"ttmEps":5.0249,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765170000000},"marketStatusCode":3,"adr":0,"adjPreClose":90.4,"symbolType":"stock","openAndCloseTimeList":[[1765157400000,1765164600000],[1765170000000,1765177200000]],"highLimit":99.44,"lowLimit":81.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2983757155,"isCdr":false,"pbRate":3.8,"roa":"--","peRate":18.169516,"roe":"19.26%","epsLYR":3.28,"committee":0.63764,"marketValue":272417000000,"turnoverRate":0.0087,"status":0,"hkstockBrief":{"symbol":"02359","market":"HK","secType":"STK","nameCN":"药明康德","latestPrice":102.9,"timestamp":1765166700004,"preClose":103,"halted":0,"volume":3088058,"delay":0,"premium":"+2.36"},"floatMarketCap":225810000000},"requestUrl":"/m/hq/s/603259","defaultTab":"news","newsList":[{"id":"2588087056","title":"药明康德（603259）披露截至11月30日证券变动月报表，12月2日股价下跌3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588087056","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588087056?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:00","pubTimestamp":1764684054,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，药明康德报收于89.42元，较前一交易日下跌3.12%，最新总市值为2668.08亿元。该股当日开盘92.03元，最高92.18元，最低89.19元，成交额达39.04亿元，换手率为1.75%。公司近日发布公告，披露了截至2025年11月30日的证券变动月报表。公告显示，无锡药明康德新药开发股份有限公司H股和A股的法定/注册股本、已发行股份均无变动。H股总数为510,476,909股，于香港联交所上市；A股总数为2,473,280,246股，于上海证券交易所上市。本月底注册股本总额为人民币2,983,757,155元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200038977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0052750758.USD","LU0708995583.HKD","LU1979443071.USD","LU2488822045.USD","BK1576","LU1969619763.USD","LU1808992512.USD","02359","LU2495084118.USD","LU2125910500.SGD","BK1583","LU1997245177.USD","LU2242644610.SGD","603259","LU0320764599.SGD","LU1046422090.SGD","161027","LU0456842615.SGD","LU2328871848.SGD","LU1934453819.USD","BK1141","LU1997245094.SGD","LU1997244956.HKD","LU2045819591.USD","BK0216"],"gpt_icon":0},{"id":"2586259735","title":"摩根大通增持药明康德(02359)约73.65万股 每股作价约102.49港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586259735","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586259735?lang=zh_cn&edition=full","pubTime":"2025-11-26 19:24","pubTimestamp":1764156293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，11月21日，摩根大通增持药明康德(02359)73.6509万股，每股作价102.4881港元，总金额约为7548.34万港元。增持后最新持股数目约为2572.02万股，持股比例为5.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1244550494.USD","LU1551013425.SGD","SG9999002224.SGD","LU0070302665.USD","LU0149725797.USD","LU1934453819.USD","BK0216","LU0971096721.USD","BK4534","BK4533","LU0251132253.USD","LU2756315318.SGD","LU0265550946.USD","LU2746668461.USD","IE00BZ1G4Q59.USD","LU1629891620.HKD","LU0211327993.USD","IE00BLSP4452.SGD","LU2462157665.USD","LU1969619763.USD","IE00BBT3K403.USD","LU2430703095.HKD","LU2430703178.SGD","LU2211815571.USD","LU1244550221.USD","SG9999002232.USD","LU0106831901.USD","IE00BYXW3230.USD","LU0211328371.USD","LU0417517546.SGD","LU1720051017.SGD","LU0320765489.SGD","LU0964807845.USD","LU0882574139.USD","LU2746668974.SGD","IE00B775SV38.USD","LU1363072403.SGD","BK1141","02359","LU1997244956.HKD","LU0708995583.HKD","LU1917777945.USD","LU2495084118.USD","603259","LU0106261372.USD","LU2023250330.USD","LU2125910500.SGD","LU2242649171.HKD","LU2430703251.USD","BK4581"],"gpt_icon":0},{"id":"2586237957","title":"药明康德：近日股东减持公司总股本的0.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586237957","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586237957?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:08","pubTimestamp":1764148088,"startTime":"0","endTime":"0","summary":"每经AI快讯，11月26日，药明康德(603259.SH)公告称，公司股东权益变动触及1%刻度。2025年10月10日，公司总股本因H股可转债转股增加至2,983,757,155股。2025年11月20日至26日，信息披露义务人通过集中竞价方式合计减持公司股份11,827,898股，占公告日公司总股本的0.40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511263575469865.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575469865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603259","LU1934453819.USD","LU2328871848.SGD","LU1997245094.SGD","LU2495084118.USD","LU1997244956.HKD","LU1997245177.USD","BK1576","LU2125910500.SGD","LU0320764599.SGD","LU1046422090.SGD","LU0456842615.SGD","LU1808992512.USD","LU0052750758.USD","LU1969619763.USD","BK1141","LU0708995583.HKD","LU2045819591.USD","LU2488822045.USD","LU1979443071.USD","BK1583","BK0216","02359","LU2242644610.SGD"],"gpt_icon":0},{"id":"2586412934","title":"药明康德“美颜”三季报：营收增18.6％ 非经常性收益支撑利润 多项指标显露增长隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2586412934","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586412934?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:24","pubTimestamp":1764051855,"startTime":"0","endTime":"0","summary":"【药明康德“美颜”三季报：营收增18.6％ 非经常性收益支撑利润 多项指标显露增长隐忧】近日，无锡药明康德新药开发股份有限公司披露了2025年第三季度报告，前三季度实现营业收入328.57亿元，同比增长18.61%；归属于上市公司股东净利润120.76亿元，同比大增84.84%。但细究业绩结构，可以看到，公司存在非经常性收益贡献显著，国内业务增长停滞、部分板块疲软、研发投入收缩等问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511253574127656.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574127656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603259","02359"],"gpt_icon":0},{"id":"2582866526","title":"每周股票复盘：药明康德（603259）可转债悉数转换新增H股1806万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866526","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582866526?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:30","pubTimestamp":1762623034,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，药明康德报收于94.84元，较上周的99.4元下跌4.59%。本周，药明康德11月3日盘中最高价报99.87元。来自股本股东变化：因可转债转换，2025年10月10日新增发行18,064,601股H股。来自公司公告汇总：药明康德将于2025年11月12日召开第三季度业绩说明会。交易信息汇总11月7日药明康德现474.2万元大宗交易。A股股份数目无变动，仍为2,473,280,246股。本月底法定/注册股本总额为人民币2,983,757,155元。所有未偿还债券已悉数转换，债券上市已于2025年10月20日撤销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02359","LU0320764599.SGD","LU1979443071.USD","LU2242644610.SGD","LU1934453819.USD","LU1808992512.USD","LU1997245177.USD","LU2488822045.USD","LU0052750758.USD","LU2125910500.SGD","LU0708995583.HKD","BK0216","BK1576","LU0456842615.SGD","LU1969619763.USD","BK1141","LU2495084118.USD","LU1997245094.SGD","LU1997244956.HKD","LU2045819591.USD","LU1046422090.SGD","LU2328871848.SGD","BK1583","603259"],"gpt_icon":0},{"id":"2581482008","title":"11月7日药明康德现474.2万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2581482008","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581482008?lang=zh_cn&edition=full","pubTime":"2025-11-07 17:20","pubTimestamp":1762507238,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日药明康德发生大宗交易，交易数据如下：大宗交易成交价格94.84元，成交5万股，成交金额474.2万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为华泰证券股份有限公司北京西三环国际财经中心证券营业部。近三个月该股共发生3笔大宗交易，合计成交1575.0手。截至2025年11月7日收盘，药明康德报收于94.84元，下跌0.89%，换手率0.95%，成交量23.4万手，成交额22.22亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700027516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","LU1969619763.USD","LU2495084118.USD","LU2045819591.USD","LU1808992512.USD","BK1576","LU1979443071.USD","LU1997244956.HKD","LU1934453819.USD","LU1997245094.SGD","LU1997245177.USD","603259","BK1583","LU2488822045.USD","LU2242644610.SGD","LU2328871848.SGD","BK0216","LU0320764599.SGD","LU0052750758.USD","LU0456842615.SGD","LU2125910500.SGD","02359","LU1046422090.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2580373082","title":"药明康德（603259）披露召开2025年第三季度业绩说明会公告，11月04日股价下跌2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580373082","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580373082?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:01","pubTimestamp":1762264864,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，药明康德报收于93.81元，较前一交易日下跌2.7%，最新总市值为2799.06亿元。该股当日开盘96.0元，最高96.02元，最低93.24元，成交额达51.41亿元，换手率为2.21%。近日，药明康德发布公告称，公司将于2025年11月12日（星期三）上午10:00-11:00通过上海证券交易所上证路演中心以视频直播和网络互动方式召开2025年第三季度业绩说明会。业绩说明会结束后，投资者可通过上证路演中心查看会议情况及主要内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400038774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0456842615.SGD","LU1997244956.HKD","LU0052750758.USD","LU1808992512.USD","BK1141","BK1583","LU0708995583.HKD","LU1969619763.USD","LU1934453819.USD","LU2488822045.USD","02359","LU0320764599.SGD","BK1576","LU2242644610.SGD","LU1997245094.SGD","LU1997245177.USD","603259","LU2495084118.USD","LU2328871848.SGD","LU2125910500.SGD","BK0216","LU1979443071.USD","LU2045819591.USD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2580260647","title":"药明康德跌3.01% 西部证券上周三维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2580260647","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580260647?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:03","pubTimestamp":1762160592,"startTime":"0","endTime":"0","summary":"中国经济网北京11月3日讯 药明康德(603259.SH)今日收报96.41元，跌幅3.01%。\r\n\r\n 西部证券股份有限公司研究员李梦园、徐子悦10月29日发布研报《药明康德(603259)季报点评：上调全年业绩指引 进一步聚焦主业提升利润率》称，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251103/31762821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02359","002673","603259"],"gpt_icon":0},{"id":"2580225457","title":"建银国际：上调药明康德(02359)目标价至131港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2580225457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580225457?lang=zh_cn&edition=full","pubTime":"2025-11-03 11:30","pubTimestamp":1762140611,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，建银国际发布研报称，上调药明康德目标价7.4%，从122港元升至131港元，维持“跑赢大市”评级。化学偶联物将有助于公司增长，TIDES在2025年前三季收入同比增121%至78亿元，主要得益于TIDES积压订单年增17%。鉴于海外客户对TIDES的需求持续增长，该行将2026年和2027年的总收入预测分别上调2%和3%，达到519亿元和585亿元；由于毛利率提高和营运支出与销售额比率下降，将2026及2027年核心盈利预期分别上调9%及12%至153及177亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","603259"],"gpt_icon":0},{"id":"2579167526","title":"中银国际：升药明康德(02359)目标价至127港元 第三季业绩胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2579167526","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579167526?lang=zh_cn&edition=full","pubTime":"2025-10-30 14:03","pubTimestamp":1761804232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中银国际发布研报称，上调药明康德2025至2027年盈利预测2.4至6.4%，H股目标价从122港元上调至127港元，对应预测明年市盈率18倍不变。报告指，撇除外汇影响，药明康德新增订单同比增长18%。药明康德管理层上调2025年自由现金流指引至80亿至85亿元;并下调资本开支至55亿至60亿元，因进度调整。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603259","02359"],"gpt_icon":0},{"id":"2579290080","title":"10月29日增减持汇总：杭氧股份拟增持 药明康德等11股拟减持（表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2579290080","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579290080?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:33","pubTimestamp":1761748380,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据统计，10月29日，盘后杭氧股份披露增持情况。包括绿田机械、江化微、药明康德、金花股份（维权）、中微公司、九洲集团、禾川科技、国瑞科技、凯伦股份（维权）、英集芯、闽东电力在内的11家A股上市公司披露减持情况。\n\n\n\n新浪声明：此消息系转载自新浪合作媒体，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-10-29/doc-infvqruh8517745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245177.USD","BK1576","BK0028","603259","LU1046422090.SGD","LU1997244956.HKD","BK1583","LU1979443071.USD","LU1688375341.USD","002430","BK1141","BK0052","BK0251","LU2328871848.SGD","LU1808992512.USD","LU2125910500.SGD","LU2495084118.USD","LU0052750758.USD","LU1934453819.USD","BK0216","LU2488822045.USD","LU1997245094.SGD","LU1969619763.USD","LU2242644610.SGD","02359","LU0320764599.SGD","LU0708995583.HKD","LU0456842615.SGD","LU2045819591.USD"],"gpt_icon":0},{"id":"1183506936","title":"药明康德股东计划减持最多合计2%的A股（股东澄清将削减A股）","url":"https://stock-news.laohu8.com/highlight/detail?id=1183506936","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183506936?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:12","pubTimestamp":1761732779,"startTime":"0","endTime":"0","summary":"药明康德股东计划减持最多合计2%的A股（股东澄清将削减A股）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245094.SGD","LU1969619763.USD","LU1979443071.USD","LU1808992512.USD","LU2328871848.SGD","LU1934453819.USD","603259","LU1997244956.HKD","LU1997245177.USD","LU2488822045.USD","BK0216","LU0456842615.SGD","LU2495084118.USD"],"gpt_icon":0},{"id":"2579397505","title":"药明康德最新公告：实际控制人控制的股东拟减持不超过2%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2579397505","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579397505?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:09","pubTimestamp":1761732589,"startTime":"0","endTime":"0","summary":"药明康德(603259.SH)公告称，实际控制人控制的股东拟减持不超过2%的公司股份。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900038427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0456842615.SGD","LU1997244956.HKD","LU0052750758.USD","LU1808992512.USD","BK1141","BK1583","LU0708995583.HKD","LU1969619763.USD","LU1934453819.USD","LU2488822045.USD","02359","LU0320764599.SGD","BK1576","LU2242644610.SGD","LU1997245094.SGD","LU1997245177.USD","603259","LU2495084118.USD","LU2328871848.SGD","LU2125910500.SGD","BK0216","LU1979443071.USD","LU2045819591.USD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2579946255","title":"业绩、效率与战略的三重奏：药明康德（02359）CRDMO模式2025 Q3全面开花","url":"https://stock-news.laohu8.com/highlight/detail?id=2579946255","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579946255?lang=zh_cn&edition=full","pubTime":"2025-10-29 10:58","pubTimestamp":1761706701,"startTime":"0","endTime":"0","summary":"在全球生物医药创新持续加速、研发需求日益多元化的背景下，药明康德发布其2025年第三季度财务报告。截至2025年前三季度，公司实现营业收入人民币328.6亿元，同比增长18.6%。反映在财务成果上，2025 年前三季度，公司整体毛利率超过46%，经调利润率突破36%。而在这一过程中，CRDMO模式的集成和全球化部署，将成为其穿越周期、实现高确定性增长的护城","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","LU0320764599.SGD","LU1979443071.USD","LU2242644610.SGD","LU1934453819.USD","LU1808992512.USD","LU1997245177.USD","LU2488822045.USD","LU0052750758.USD","LU2125910500.SGD","LU0708995583.HKD","BK0216","BK1576","LU0456842615.SGD","LU1969619763.USD","BK1141","LU2495084118.USD","LU1997245094.SGD","LU1997244956.HKD","LU2045819591.USD","LU1046422090.SGD","LU2328871848.SGD","BK1583","603259"],"gpt_icon":0},{"id":"2578984282","title":"高盛：药明康德(02359)上季盈利胜预期 关注新订单动能与临床CRO业务 目标价109.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578984282","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578984282?lang=zh_cn&edition=full","pubTime":"2025-10-28 14:44","pubTimestamp":1761633898,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，预期市场对药明康德 强劲的业绩表现，和新订单动能将作出正面反应，虽然围绕TIDES订单储备增长放缓可能引发一些争议。药明康德第三季度收入达121亿元人民币，同比增长15.3%，或按持续经营业务计算则同比增长19.7%。高盛对药明康德港股12个月目标价为109.6港元，基于12个月前瞻市盈率18倍，药明康德为目标价105.6元人民币。高盛指，药明康德第三季资本支出为14.7亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","603259"],"gpt_icon":0},{"id":"2578424985","title":"【券商聚焦】招银国际维持药明康德(02359)“买入”评级 惟指全面复苏仍需时间","url":"https://stock-news.laohu8.com/highlight/detail?id=2578424985","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578424985?lang=zh_cn&edition=full","pubTime":"2025-10-28 13:32","pubTimestamp":1761629537,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，药明康德 公布强劲的3Q25财报， 收入同比增长15.3% ，其中持续经营收入同比增长19.7%，经调整Non-IFRS归母净利润同比显著增长42.0%。截至3Q25， 药明康德的持续经营在手订单金额达到598.8亿元，同比增长41.2%，相比截至2Q25的同比增速37.2%进一步加速。管理层表示，得益于国内资本市场的复苏、火热的全球BD交易以及美国降息等宏观环境的改善，药明康德看到了一些早期需求复苏的信号，但行业的全面复苏仍需时间观察。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968608","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","603259"],"gpt_icon":0},{"id":"2578097186","title":"高瓴拟斥资28亿买下药明康德旗下康德弘翼和津石医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2578097186","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578097186?lang=zh_cn&edition=full","pubTime":"2025-10-28 09:34","pubTimestamp":1761615251,"startTime":"0","endTime":"0","summary":"药明康德称，全资子公司上海药明康德新药开发有限公司拟以人民币28亿元的对价向上海世和融企业管理咨询有限公司及上海世和慕企业管理咨询有限公司转让其所持有的上海康德弘翼医学临床研究有限公司（简称“康德弘翼”）和上海药明津石医药科技有限公司（简称“津石医药”，与“康德弘翼”）100%股权。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251028/6389724084199212193435234.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251028/6389724084199212193435234.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n31579/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LU1934453819.USD","BK1141","603259","LU1808992512.USD","BK0216","02359","LU2488822045.USD","09939","159938","LU0052750758.USD","LU2125910500.SGD","LU2495084118.USD","BK1583","LU2328871848.SGD","LU0708995583.HKD","LU2242644610.SGD","BK1515","LU1979443071.USD","BK1576","LU0320764599.SGD","LU1997245094.SGD","LU1969619763.USD","LU1997244956.HKD","LU2045819591.USD","BK1161","LU0456842615.SGD","LU1046422090.SGD","LU1997245177.USD","BK1574"],"gpt_icon":0},{"id":"2578267039","title":"华宝基金胡洁旗下华宝中证医疗ETF三季报最新持仓，重仓药明康德","url":"https://stock-news.laohu8.com/highlight/detail?id=2578267039","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578267039?lang=zh_cn&edition=full","pubTime":"2025-10-28 07:33","pubTimestamp":1761607985,"startTime":"0","endTime":"0","summary":"证券之星消息，10月28日华宝基金旗下胡洁管理的华宝中证医疗交易型开放式指数基金公布三季报，近1年净值增长率6.63%。其中药明康德持仓占比14.58%，为该基金第一大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800008190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2125910500.SGD","LU2488822045.USD","BK1141","LU2242644610.SGD","LU1979443071.USD","LU1997245177.USD","LU0708995583.HKD","LU1969619763.USD","159828","BK1583","LU1934453819.USD","LU0052750758.USD","603259","LU1997245094.SGD","LU1997244956.HKD","02359","LU2328871848.SGD","BK1576","LU0320764599.SGD","LU1046422090.SGD","512170","LU2045819591.USD","LU0456842615.SGD","LU2495084118.USD","BK0216","LU1808992512.USD"],"gpt_icon":0},{"id":"2578461987","title":"大摩：药明康德(02359)有望超越全年收入增长指引 予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2578461987","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578461987?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:19","pubTimestamp":1761556763,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，药明康德第三季收入同比升15.3%至121亿元人民币(下同)，净利润升53.3%至35.15亿元，经调整非国际财务报告准则净利润升42%至42.2亿元，胜该行预期。该行又认为目前是购入药明康德股份的合适时机，因现时该股2026财年预测市盈率约20倍，低于行业中位数的26倍;予其“增持”评级，A股目标价105元人民币。公司首九个月收入已累计同比增长22.5%，该行认为其全年表现有望达到甚至超越指引。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603259","02359"],"gpt_icon":0},{"id":"2578615016","title":"瑞银：药明康德季绩超预期 上调目标价至138.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578615016","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578615016?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:01","pubTimestamp":1761555660,"startTime":"0","endTime":"0","summary":" 瑞银发布研报称，上调对药明康德今年每股盈利预测23.4%，明年至2028年盈测上调0.3%至0.9%。对该股目标价由136.1港元上调至138.4港元，评级“买入”。 药明康德第三季收入同比升15%至121亿元人民币，超出该行及市场预估的114亿元及115亿元人民币；纯利同比升53%至35亿元人民币，高于该行及市场预估的33亿元及31亿元人民币。截至第三季末持续营运订单储备同比升41%至599亿元人民币。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-10-27/doc-infvinsm5150411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603259","02359"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765167434711,"stockEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0415},{"period":"3month","weight":-0.1555},{"period":"6month","weight":0.4172},{"period":"1year","weight":0.8025},{"period":"ytd","weight":0.6836}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"无锡药明康德新药开发股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"274055人(较上一季度增加16.39%)","perCapita":"9024股","listingDate":"2018-05-08","address":"江苏省无锡市滨湖区马山五号桥","registeredCapital":"298375万元","survey":" 无锡药明康德新药开发股份有限公司的主营业务是为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务。公司的主要产品是化学业务、测试业务、生物学业务。公司的服务能力和规模在行业处于领先地位,拥有了多项行业领先的技术和能力。","listedPrice":21.6},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明康德(603259)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明康德(603259)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明康德,603259,药明康德股票,药明康德股票老虎,药明康德股票老虎国际,药明康德行情,药明康德股票行情,药明康德股价,药明康德股市,药明康德股票价格,药明康德股票交易,药明康德股票购买,药明康德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明康德(603259)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明康德(603259)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}